trending Market Intelligence /marketintelligence/en/news-insights/trending/2LFA8pT-fb4zVEgB201DQQ2 content esgSubNav
In This List

Catalyst Pharmaceuticals plans common stock offering

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Catalyst Pharmaceuticals plans common stock offering

Catalyst Pharmaceuticals Inc. plans to offer and sell up to 11 million common shares in an underwritten public offering.

The company plans to grant underwriters an overallotment option to buy up to an additional 15% of the shares offered.

Net proceeds will be used to fund clinical studies of company's drug Firdapse and to fund its precommercialization activities, and for general corporate purposes.

Piper Jaffray & Co. is acting as the lead book runner. SunTrust Robinson Humphrey Inc. is also acting as a book runner.